Punctate Palmoplantar Keratoderma Type 1
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Kamari PharmaIsrael - Ness Ziona
2 programs2
KM-001 cream 1% 12 weeks treatment.Phase 11 trial
Serum chemistryPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Kamari PharmaKM-001 cream 1% 12 weeks treatment.
Kamari PharmaSerum chemistry
Clinical Trials (2)
Total enrollment: 32 patients across 2 trials
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC
Start: Mar 2023Est. completion: Nov 202418 patients
Phase 1Completed
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases
Start: Jul 2022Est. completion: Sep 202414 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.